FDA– tag –
-
Celularity and MuseCell Innovations® Forge US Manufacturing Partnership, Projecting Over $300M in Purchases for Dezawa MuseCell® Platform
Celularity (Press Release) USA Overview Celularity Inc. announced a US manufacturing collaboration with MuseCell Innovations®, with Celularity's Florham Park, NJ facility set to produce Dezawa MuseCells® and related products. This partne... -
Franciscan Health Advances Cancer Care with CAR-T Cell Therapy and Bone Marrow Transplants, Addresses Donor Matching Challenges
Franciscan Health USA Overview Franciscan Health Cancer Center Indiana Blood & Marrow Transplantation is spearheading advancements in cancer treatment through cellular therapies, including CAR-T cell therapy and bone marrow transplan... -
Technology Networks Delineates Commercialization Strategies for iPSC Therapies: Automated Manufacturing and Immune-Evasive Cell Line Development are Key
Technology Networks UK Overview Technology Networks provides an in-depth analysis of strategic challenges and solutions for the commercial viability of iPSC-based therapies, emphasizing the critical importance of scalable manufacturing, ... -
Dexcom Gains FDA Clearance for G7 15-Day CGM and Smart Basal, Joins TEMPO Pilot Program
Simply Wall St USA Overview Dexcom has secured FDA clearance for its Dexcom G7 15-Day continuous glucose monitoring (CGM) system, extending wear time to 15.5 days for all types of adult diabetes patients. Simultaneously, Dexcom Smart Bas... -
FDA Reiterates No Non-Invasive Glucose Monitors Approved; Tech Giants Pursue Inferential Wearables
Medium (Sahha AI Blog) USA Overview As of September 2026, the FDA has reiterated that no non-invasive glucose monitoring devices are approved, cautioning consumers against smartwatches or rings claiming to measure blood sugar without ski... -
Abbott’s Libre Duo 10 Day System Receives FDA De Novo Clearance as First Integrated Continuous Glucose-Ketone Monitor
Pharmacy Times USA Overview Abbott's Libre Duo 10 Day system has received FDA De Novo clearance, becoming the first integrated continuous glucose-ketone monitoring (iCGK) system in the U.S. and the world's first wearable device to track ... -
Nanoparticle-Based Drug Delivery Proven Clinically Feasible for Cancer and Genetic Disorders, Highlighted by Doxil® Success
MDPI Switzerland Overview Nanoparticle-based drug delivery systems have achieved clinical success in multiple oncological and genetic disorder indications, demonstrating their translational potential. Doxil® (liposomal doxorubicin), FDA-... -
Cellipont Bioservices’ Texas Facility Propels Six Client Cell Therapy Programs to Expected 2026 IND Submissions
PR Newswire (Cellipont Bioservices) USA Overview Cellipont Bioservices, a cell therapy CDMO, announced that its Texas facility has supported six client projects anticipated to reach Investigational New Drug (IND) submission in 2026. This... -
Overcoming Commercialization Hurdles for iPSC Therapeutics: Regulatory Compliance and Accessible Manufacturing Strategies
Technology Networks Unknown Overview Commercializing iPSC-based therapeutics faces significant challenges in regulatory compliance and ensuring patient accessibility, as many therapies originate from academic settings without large-scale... -
UniQure Files for FDA Approval of Huntington’s Gene Therapy AMT-130, Pursuing Breakthrough for Neurological Disorder
BioPharma Dive USA Overview After overcoming previous regulatory challenges, UniQure has submitted its gene therapy AMT-130 for FDA approval, aiming to be the first medicine to address the underlying cause of Huntington's disease. The co...
